EQUITY RESEARCH MEMO
Horus Pharma
Generated 5/11/2026
Executive Summary
Conviction (model self-assessment)65/100
Horus Pharma is an independent French pharmaceutical company founded in 2003, specializing in ophthalmology and dermatology. It is a pioneer in preservative-free ophthalmic products, with a portfolio spanning medicinal products, medical devices, food supplements, and a surgical division. The company operates internationally through subsidiaries across Europe and distribution agreements in numerous other countries, leveraging its expertise in niche therapeutic areas. Its focus on preservative-free solutions addresses growing demand for safer ocular treatments, positioning it as a key player in the European ophthalmology market.
Upcoming Catalysts (preview)
- Q3 2026Launch of new preservative-free ophthalmic product70% success
- Q4 2026Expansion of surgical division into new European markets60% success
- TBDStrategic partnership for dermatology product distribution50% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)